The resolution designates March as “Deep Vein Thrombosis and Pulmonary Embolism Awareness Month,” reciting prevalence, mortality, risk factors, and estimated annual costs for venous thromboembolism (VTE). It lists specific risk groups — cancer patients, pregnant and postpartum people, immobilized or postoperative patients, older adults, and those with inherited clotting disorders — and frames DVT and PE as largely preventable causes of hospital death.
Because this is a simple House resolution, it creates no new regulatory duties or funding streams. Its practical effect is symbolic: it provides a federal imprimatur that stakeholders can cite when promoting screening, prevention protocols, clinician education, public outreach, or agency communications about VTE risk and prevention.
At a Glance
What It Does
The resolution formally names March as an awareness month for deep vein thrombosis (DVT) and pulmonary embolism (PE), enumerates incidence, mortality, cost estimates, and common risk factors, and states support for the month’s goals and the importance of raising awareness. It contains no authorization of spending and imposes no legal obligations.
Who It Affects
Clinicians, hospitals, oncology and maternal health programs, public health agencies, and patient advocacy groups are the primary audiences likely to use the designation to coordinate outreach, education, and quality-improvement efforts. Insurers and employers are indirectly affected if awareness drives demand for prevention or screening.
Why It Matters
Symbolic Congressional recognition can catalyze coordinated campaigns and lend weight to grant applications or agency messaging, even without appropriations. For clinicians and health systems, the designation supplies an external reference point to prioritize VTE prevention activities and patient education.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution opens with a sequence of "whereas" clauses that summarize current evidence and policy-relevant facts: DVT is clotting in deep veins (most commonly the leg), PE is a potentially fatal complication when clots travel to the lung, and together these conditions affect up to 900,000 people and cause an estimated 60,000 to 100,000 deaths annually in the United States. The preamble also highlights specific risk factors — cancer, pregnancy and the postpartum window, immobility, surgery, older age, and hereditary clotting disorders — and attaches a rough annual cost figure of $10 billion.
Following the preamble, the operative portion contains two short provisions: (1) a statement that Congress supports the goals and ideals of establishing March as the designated awareness month, and (2) an express recognition of the importance of raising awareness about DVT and PE. The text does not direct any federal agency to take action, does not create reporting or monitoring requirements, and does not appropriate funds.In practice, stakeholders will treat the resolution as a signaling mechanism.
Public health departments, professional societies, and patient groups can reference the congressional designation when launching education campaigns, updating clinical pathways, or advocating for research and prevention funding. Health systems could use the month to intensify existing VTE prophylaxis and mobility protocols or to run quality-improvement projects, although the resolution does not compel such changes.Finally, because the resolution is declarative rather than regulatory, its downstream impact depends on whether federal agencies, state programs, or private actors elect to follow through with concrete programs.
The document offers a factual frame and a rhetorical tool, but it leaves implementation choices — who leads campaigns, what metrics to use, whether to fund interventions — entirely to others.
The Five Things You Need to Know
The resolution designates March as “Deep Vein Thrombosis and Pulmonary Embolism Awareness Month.”, The preamble cites incidence and mortality figures contained in the text: up to 900,000 U.S. cases of DVT/PE per year and 60,000–100,000 deaths annually.
The resolution identifies specific high-risk populations and drivers: cancer patients, pregnancy (with elevated risk up to three months postpartum), immobility, surgery, older age, and family history of clotting/thrombophilia.
The measure is purely symbolic: it expresses support and recognition but does not mandate action, create reporting obligations, or authorize federal spending.
The resolution was introduced in the House by Rep. Greg Murphy (with Rep. Tonko) and referred to the House Committee on Energy and Commerce.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statement of facts about DVT/PE burden and risk factors
This set of clauses gathers incidence, mortality, cost estimates, and known risk factors into the legislative record. For practitioners and advocates, the preamble is the factual backbone: it supplies statistics and identifies populations to target for outreach (cancer patients, pregnant and postpartum people, postoperative and immobile patients). Because resolutions place facts on the congressional ledger, these clauses can be cited in testimony, grant proposals, and agency communications.
Support for the goals and ideals of the Awareness Month
This operative sentence declares Congress’ support for the month’s objectives. Its practical effect is communicative: it legitimizes stakeholder campaigns and may be used by organizations to justify concentrating outreach or quality-improvement efforts in March. There is no legal enforcement mechanism; the clause serves as political backing rather than a policy mandate.
Recognition of the importance of raising awareness
This provision reinforces the first resolved clause by expressly recognizing the value of awareness. In implementation terms, it signals to federal, state, and local health agencies that Congress views VTE education as a priority, which may influence discretionary agency messaging, coordination with professional societies, or prioritization of public-health communication calendars.
No authorization, appropriation, or regulatory change
The resolution contains no funding authorization, no directive to agencies, and no change to existing law or regulatory frameworks. Any follow-on programs—public education campaigns, updated clinical guidance, or funded prevention initiatives—would require separate appropriations or rulemaking. Stakeholders should treat the measure as a rhetorical device that can be leveraged rather than an implementation blueprint.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients at risk for VTE: The designation amplifies public messaging that can increase recognition of symptoms and encourage early care-seeking, potentially reducing preventable morbidity and mortality.
- Patient advocacy and professional societies: The congressional imprimatur strengthens fundraising appeals, media outreach, and partnership opportunities during the designated month.
- Hospitals and clinicians focused on patient safety: Health systems can use the awareness month to justify concentrated quality-improvement efforts on prophylaxis, mobility protocols, and discharge education.
- Maternal health programs: Explicit mention of pregnancy and the postpartum period provides a platform for maternal health organizations to integrate VTE education into prenatal and postnatal services.
Who Bears the Cost
- Federal agencies (potential soft costs): If agencies choose to run awareness campaigns in response, they will absorb staff time and messaging costs without new appropriations unless funded separately.
- Hospitals and health systems (operational costs): Organizations that intensify screening, prophylaxis, or patient-education activities during the month may face marginal staffing and supply costs.
- Nonprofit advocacy groups (execution burden): Smaller advocacy organizations may feel pressure to produce campaigns or events during March and may need to reallocate limited resources to participate.
Key Issues
The Core Tension
The central tension is between the utility of a low-friction, symbolic congressional endorsement to raise awareness and the risk of creating public and stakeholder expectations for concrete action without providing funding, implementation guidance, or evidence-based priorities—raising attention is useful, but without follow-through the public health impact may be limited and costs may fall unevenly on health systems and agencies.
The resolution creates a clear, usable signal without any funding or legal teeth. That has benefits—low political friction, immediate citation value for advocates—but it also creates a follow-through problem: public expectations for action can rise without any designated agent, budget, or measurable objectives.
The text attaches specific statistics and a $10 billion annual cost estimate; those figures strengthen advocacy but also carry uncertainty and range, which can be marshaled selectively by different stakeholders.
Implementation questions are left unresolved. The resolution does not identify which federal or state entities should lead awareness activities, what evidence-based prevention strategies to prioritize, or how to measure impact.
If the designation drives expanded prophylaxis or screening, it may shift costs to hospitals or insurers without clear evidence about net benefit in all settings. Finally, the resolution includes an internal drafting quirk (it is an H.
Res. but the operative clause addresses "the Senate"), a technicality that does not change substance but may require correction for precise legislative record-keeping.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.